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Summary
 
Immune evasion is critical for survival of viruses that establish persistent or recurrent infections.
However, at the molecular level, little is known about how viruses evade immune attack in
vivo. Herpes simplex virus (HSV)-1 glycoprotein gC has two domains that are involved in
modulating complement activation; one binds C3, and the other is required for blocking C5
and properdin (P) binding to C3. To evaluate the importance of these regions in vivo, HSV-1
gC mutant viruses were constructed that lacked one or both gC domains and studied in a mu-
rine model of infection. Each gC region of complement regulation contributed to virulence;
however, the C3 binding domain was far more important, as virus lacking this domain was
much less virulent than virus lacking the C5/P inhibitory domain and was as attenuated as virus
lacking both domains. Studies in C3 knockout mice and mice reconstituted with C3 con-
firmed that the gC domains are inhibitors of complement activation, accounting for a 50-fold
difference in virulence between mutant and wild-type viruses. We conclude that the C3 bind-
ing domain on gC is a major contributor to immune evasion and that this site explains at a mo-
lecular level why wild-type virus resists complement attack.
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H
 
erpes simplex virus has developed many strategies for
survival in the human host. One of the most success-
ful is its ability to establish latent infection in neurons with-
out expressing viral proteins that serve as targets for immune
attack (1, 2). However, during latency, virus cannot spread
person to person; therefore, the virus must reactivate to
successfully infect another host. HSV has the ability to rep-
licate for days after reactivation in the immune host, which
may be related to viral immune evasion strategies. HSV-1
immune evasion molecules block activities of antibodies
(3–7) and complement (8–10) and prevent antigen presen-
tation by the MHC class I complex (11, 12). Molecules
that perform similar functions have been identified in ade-
noviruses, vaccinia virus, and other members of the herpes
virus family (13–18).
HSV-1 glycoprotein gC is among the best characterized
of the viral immune evasion molecules. gC binds comple-
ment components C3, C3b, iC3b, and C3c, accelerates the
decay of the alternative pathway C3 convertase, and blocks
the interaction of C5 and
 
 
 
properdin (P)
 
1
 
 
 
with C3 (9, 19, 20).
The C5 and
 
 
 
P
 
 
 
blocking domain is near the NH
 
2
 
 terminus,
whereas the C3 binding domain is in the central region of
the molecule (9, 21). gC inhibits complement activation (9,
20), protects cell free virus from complement-mediated
neutralization (10, 22, 23), inhibits complement-mediated
lysis of HSV-infected cells (24, 25), and protects the virus
against complement attack in vivo (26).
Vaccines incorporating molecules required for virus en-
try, including glycoproteins gB and gD, failed to prevent
infection and had little effect on recurrence rates (27–29).
A better understanding of HSV immune evasion strategies
may be required to design more effective vaccines. With
this goal in mind, we evaluated virulence of gC mutant vi-
ruses deleted in the C3 binding domain, the C5/P blocking
domain, or both to define the contributions of each do-
main to immune evasion. We chose to study gC–comple-
ment interactions in mice because C3 knockout mice are
available to establish the importance of C3. We selected the
murine flank model, as we previously showed that comple-
ment significantly contributes to defense against HSV-1 in
this model (24). We used C3 reconstitution (30) to confirm
that gC is highly effective in protecting wild-type virus
from complement attack and to define an impressive role
for the C3 binding domain in pathogenesis.
 
Materials and Methods
 
Construction of gC Mutant Viruses.
 
HSV-1 strain NS, a low pas-
sage clinical isolate, was the parental strain for the mutant viruses.
 
1
 
Abbreviation used in this paper:
 
 P, properdin. 
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NS-gCnull virus has the entire gC protein coding sequence re-
placed by a 
 
lacZ
 
 expression cassette under the control of the HSV-1
infected cell protein 6 early promoter, as previously described (23).
NS-gC
 
D
 
C5/P virus has a deletion of the gC domain involved in
blocking C5 and
 
 
 
P binding to C3 (9, 21). This deletion was con-
structed from the NS BamH1 “I” fragment (reference 31; nucleo-
tides 91,602–98,254; sequence available from EMBL/GenBank/
DDBJ under accession numbers X14122, D00317, D00374,
S40493, and XD2138) by cutting with Nsi1 and EcoR1 and
cloning this fragment (nucleotides 94,911–96,751) into pGEM7Z
(Promega Corp.) to create plasmid pLW1. An Nhe1–EcoR1 frag-
ment (nucleotides 96,276–96,751) was excised from pLW1 and
cut with Apa1 to delete 91 gC amino acids (amino acids 33–123;
nucleotides 96,407–96,679). The Nhe1–EcoR1 fragment deleted
of gC amino acids 33–123 was inserted back into pLW1, and
then the Nsi1–EcoR1 fragment from pLW1 was cloned back
into the BamH1 I fragment to create a flanking sequence vector
with a deletion of the gC C5/P domain.
gC
 
D
 
C3 has a deletion of 92 amino acids (gC amino acids 275–
367), prepared by cutting plasmids B29 and H71 (32) with BglII,
religating the 5
 
9
 
 portion of B29 with the 3
 
9
 
 portion of H71, and
then cloning this fragment into the EcoR1–EcoRV site of the
BamH1 I fragment. The construction adds a 12-mer BglII linker
after gC amino acid 275 and creates a flanking sequence vector
that has a deletion of two gC C3 binding regions, resulting in a
net loss of 88 amino acids.
A flanking sequence vector to construct gC
 
D
 
C5/P,C3 was
prepared by replacing the BamH1 I EcoR1–EcoRV fragment in
the gC
 
D
 
C5/P flanking sequence vector with the EcoR1–EcoRV
fragment of the gC
 
D
 
C3 flanking sequence vector. Recombinant
viruses were prepared in Vero cells by cotransfection using NS-
gCnull virus DNA and the various flanking sequence vectors.
Recombinant viruses were identified by anti-gC immunoperoxi-
dase staining of infected cells (21). Virus pools were prepared af-
ter three rounds of plaque purification.
 
Sucrose Gradient Purification of Virus.
 
Vero cells were infected
at an MOI of 5 for 20 h at 37
 
8
 
C, and then virus from supernatant
fluids was purified on a 5–65% sucrose gradient (23). The visible
virus band was collected, dialyzed against PBS at 4
 
8
 
C, and stored at
 
2
 
70
 
8
 
C. Virus titers were determined by plaque assay on Vero cells.
 
One-Step Growth Curves.
 
Vero cells were inoculated at an MOI
of 5, and at 1, 4, 8, 12, 20, and 24 h after infection, cells plus su-
pernatant fluids were harvested, cells were lysed by sonication,
and viral titers were determined by plaque assay.
 
Southern Blot Analysis.
 
DNA was digested with BamH1 and
 
HincII, electrophoresed in 1.2% agarose gels, transferred to Immo-
bilon-S membranes (Millipore Corp.), and UV cross-linked. A bi-
otin-labeled gC-1 fragment spanning the entire protein coding se-
quence (nucleotides 96,276–97,945) was used as probe, and bands
were detected by chemiluminescence (New England Biolabs) (6).
 
Western Blot Analysis.
 
Purified virus was run on 10% SDS-
PAGE, transferred to Immobilon-P membranes (Millipore Corp.),
and visualized using polyclonal rabbit anti-gC antibody and
horseradish peroxidase–conjugated goat anti–rabbit IgG (Amer-
sham Pharmacia Biotech) (23).
 
Antibody-independent Complement Neutralization.
 
Neutraliza-
tion assays were performed by incubating 10
 
4
 
–10
 
5
 
 PFU of puri-
fied virus with HSV-1 and -2–seronegative human serum as the
source of complement for 1 h at 37
 
8
 
C. As a control, complement
was inactivated by heat treatment at 56
 
8
 
C for 30 min. Virus titers
were then determined by plaque assay on Vero cells. Comple-
ment neutralization was calculated as the difference in titers be-
tween virus incubated with active or heat-inactivated serum (23).
 
C3b Rosetting Assays.
 
Vero cells were infected at an MOI of
2 for 20 h, and then cells were removed using cell dissociation
buffer (GIBCO BRL), incubated with C3b-coated erythrocytes
for 1 h at 37
 
8
 
C, and viewed by microscopy for rosettes. Cells with
four or more bound erythrocytes were considered positive (23).
 
C3 Purification.
 
Human C3 was purified according to Ham-
mer et al. (33) with modifications. 20 parts human plasma were
treated with 1 part inhibitor containing 1 M KH
 
2
 
PO
 
4
 
, 0.2 M
Na
 
4
 
EDTA, 0.2 M benzamidine, and 1 mM PMSF. C3 was pre-
cipitated from plasma first with 4.5% polyethylene glycol (PEG)
and then with 12% PEG at 0
 
8
 
C. The pellet was dissolved in
buffer A (20 mM Na
 
2
 
HPO
 
4
 
, pH 7.4) and loaded onto a DEAE
40HR column (5 
 
3 
 
6.3 cm; Waters) preequilibrated with buffer
A. The bound proteins were eluted using a 0–0.5 M NaCl linear
salt gradient. Fractions containing C3 were detected by SDS-PAGE
and immunodiffusion, dialyzed against buffer A, loaded onto a
Mono Q HR 10/10 column (Amersham Pharmacia Biotech), and
eluted with a linear salt gradient to 0.5 M NaCl. Homogeneous
C3 fractions were identified by SDS-PAGE and immunodiffu-
sion, pooled, and dialyzed against PBS (10 mM Na
 
2
 
HPO
 
4
 
 and
145 mM NaCl, pH 7.4). The purified C3 contained 80% native
C3 and 20% C3(H
 
2
 
O), as determined by analyzing the protein
sample on a Mono S column (Amersham Pharmacia Biotech) (34).
 
Murine Flank Model.
 
The flank model and the C3 knockout
mice derived from C57BL/6 mice have been described previously
(26, 35). In brief, purified virus was scratched onto the flank that
was shaved and chemically denuded. Disease at the inoculation
Figure 1. Stick diagram of wild-type and
mutant gC proteins. The top stick figure
shows wild-type gC with a signal sequence
(SIG), transmembrane domain (TM), the
C5/P blocking domain, and four regions
(labeled I–IV) shown as shaded ovals that
are required for C3 binding. Black balloons
show the positions of N-linked glycosy-
lation sites. Cysteines are indicated (C), and
lines joining two Cs reflect disulfide bond-
ing pattern. The second stick figure shows
the deletion from amino acids 33–123 that
eliminates the C5/P blocking domain. The
third stick figure shows the deletion from
amino acids 275–367 that eliminates C3
binding domain regions II and III. The
fourth (bottom) stick figure shows the dou-
ble deletion that eliminates the C5/P block-
ing and the C3 binding domain. 
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site first appeared on day 3 and was scored as follows: erythema or
swelling with no vesicles was assigned 0.5 points; individual vesi-
cles were scored as 1 point each with a total maximum daily score
of 5. If lesions coalesced, up to 5 points were assigned based on
the size of the lesions. Zosteriform disease first appeared on day 4
or 5 and was scored similarly, except that the maximum daily
score was 10 because more lesions could be counted over the
larger skin area involved.
C3 reconstitution experiments were performed by intraperito-
neal injection of C3 knockout mice using 3 mg of human C3 per
mouse. C3 knockout mouse serum was assayed for total hemo-
lytic complement activity before and after reconstitution with
human C3 as described (36).
 
Results
 
Characterization of gC Mutant Viruses.
 
Features of wild-
type gC and three gC mutants are shown in Fig. 1. Wild-
type gC (Fig. 1, top) has four C3 binding regions (light
gray), each of which is required to bind C3 (32). The gC
domain that interferes with C5 and
 
 
 
P binding to C3 is lo-
cated at the NH
 
2
 
-terminal region between residues 33 and
123 (9, 21). gC
 
D
 
C5/P mutant (Fig. 1, second from top)
contains a deletion of gC amino acids 33–123. gC
 
D
 
C3
mutant (Fig. 1, third from top) has a deletion of amino ac-
ids 275–367 that includes C3 binding regions II and III.
This deletion removes a disulfide-bonded cysteine pair (37)
to minimize the effect of the deletion on gC conformation.
gC
 
D
 
C5/P,C3 mutant (Fig. 1, bottom) has both domains
deleted that interact with complement.
The mutant gC proteins were recombined into virus,
and the size of the gC DNA was evaluated by Southern
blot analysis. HSV-1 was cut with BamH1 and HincII to
cut once within the gC gene and probed with sequences
spanning the entire gC protein coding sequence. Fig. 2 A
(left blot) shows two gC bands for wild-type NS and
smaller upper bands for gC mutant viruses NS-gC
 
D
 
C5/P,
C3 and NS-gC
 
D
 
C3; the right blot shows the smaller upper
band for gC mutant NS-gC
 
D
 
C5/P. Bands were of the ex-
pected size for each of the gC mutant viruses. Western
blots were performed on purified virus to demonstrate that
mutant gC glycoproteins are incorporated into the virion
and are of the expected size (Fig. 2 B). The double mutant
virus NS-gC
 
D
 
C5/P,C3 makes the smallest of the three
mutant proteins. NS-gC
 
D
 
C5/P has a deletion of 91 amino
acids and on SDS-PAGE runs smaller than NS-gC
 
D
 
C3,
which has a deletion of 88 amino acids. However, the dif-
ference in migration of the two glycoproteins was greater
than expected based on amino acid size. A likely explana-
tion is that five N-linked glycosylation sites and numerous
predicted O-linked glycosylation sites lie within the de-
leted domain of NS-gC
 
D
 
C5/P, whereas one N-linked and
few O-linked glycosylation sites lie within the deleted frag-
ment of NS-gC
 
D
 
C3.
The kinetics of virus replication and peak titers achieved
for each gC mutant virus were similar to those of wild-type
Figure 2. Southern blot (A)
and Western blot (B) of wild-
type and gC mutant viruses. (A)
Left panel: DNA from wild-type
virus, NS, and gC mutant viruses
NS-gCDC5/P,C3 and NS-
gCDC3 was cut with BamH1
and HincII to generate two gC
fragments of different sizes con-
sistent with the deletion muta-
tions introduced. Right panel:
DNA from NS and gC mutant
virus NS-gCDC5/P was cut
with the same restriction en-
zymes as above. (B) Western blot
of purified viruses showing wild-
type (NS) gC protein and the
smaller proteins made by each of
the mutant viruses NS-gCDC5/P, NS-gCDC3, and NS-gCDC5/P,C3.
No gC protein is detected in the gCnull virus lane.
Figure 3. C3b binding was assessed by a rosetting assay. Wild-type vi-
rus, NS, and NS-gCDC5/P (C5/P) form rosettes, whereas NS-gCDC3
(C3), NS-gCDC5/P,C3 (C5/P,C3), and NS-gCnull (gCnull) viruses do
not form rosettes.
Figure 4. Antibody-independent complement neutralization of wild-
type virus, gEnull mutant virus, and a panel of gC mutant viruses. 104–105
PFU of purified virus was incubated with HSV-1 and -2 antibody–nega-
tive human serum as a source of complement or heat-inactivated serum as
control. After a 1-h incubation at 378C, virus titers were determined by
plaque assay. Results are expressed as the differences in titers (log10) 6
SEM comparing virus incubated with inactivated complement or active
complement. NS, wild-type HSV-1; gEnull, gE deletion virus NS-gEnull
(6) derived from NS; C5/P, NS-gCDC5/P; C3, NS-gCDC3; C5/P,C3,
NS-gCDC5/P,C3; gCnull, NS-gCnull. Experiments were performed
three to five times, as indicated by the numbers above the bars. 
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Figure 5. Lesion scores in mice infected with wild-type or gC mutant viruses. The left panels (A, C, and E) show disease scores 6 SEM at the inocu-
lation site, and the right panels (B, D, and F) show disease scores 6 SEM at the zosteriform spread site. A and B demonstrate disease scores in comple-
ment-intact mice (normal mice), C and D in C3 knockout mice, and E and F in C3 knockout mice reconstituted with human C3. WT, virus NS; C5,
NS-gCDC5/P; C3, NS-gCDC3; C5,C3, gC double mutant virus NS-gCDC5/P,C3. The numbers of animals evaluated in each group are indicated in
the legends at right. 
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virus when evaluated by single-step growth curves (result
not shown). gC protein expression at the infected cell sur-
face was confirmed for each mutant virus by immunoper-
oxidase staining, and the ability of gC to bind C3b was de-
termined by rosetting assays. Mutant viruses NS-gC
 
D
 
C3,
NS-gC
 
D
 
C5/P,C3, and NS-gCnull lack the C3 binding
domain and fail to form C3b rosettes, whereas NS and NS-
gC
 
D
 
C5/P mutant viruses have the C3 binding domain and
form rosettes (Fig. 3). The results suggest that the gC muta-
tions have not drastically altered protein conformation, as
mutant virus NS-gC
 
D
 
C5/P formed rosettes, and each mu-
tant virus incorporated gC into the envelope and expressed
gC at the infected cell surface.
 
gC Domains that Interact with Complement Protect the Virus
from Complement Neutralization.
 
Previously, we reported
that HSV-1 lacking the entire gC protein is rapidly neutral-
ized by human complement, showing 50% neutralization
within 2 min and 100–5,000-fold neutralization by 1 h, the
higher number occurring if fresh complement was added
during the hour-long incubation. In contrast, wild-type vi-
rus is resistant to complement (less than or equal to twofold
neutralization; reference 23). The panel of gC mutant vi-
ruses was incubated with HSV-1 and -2 antibody–negative
human serum as source of complement for 1 h or comple-
ment-inactivated serum as a control, and viral titers were
determined. A glycoprotein gE mutant virus derived from
NS (6) served as a control for the effects of removing a gly-
coprotein from the virion envelope. gE lacks complement
interacting domains. Complement has a small effect on NS
and NS-gEnull viruses (0.3 log
 
10
 
 and 0.35 log
 
10
 
, respectively;
Fig. 4). gC mutant virus lacking the C5/P blocking domain
was relatively resistant to complement (0.43 log
 
10
 
,
 
 P 
 
5 
 
0.22
or 0.76, comparing NS-gC
 
D
 
C5/P with NS or NS-gEnull,
respectively). The gC mutant virus lacking the C3 binding
domain was somewhat more susceptible to complement
(0.66 log
 
10
 
,
 
 P 
 
5 
 
0.01 or 0.1, comparing NS-gC
 
D
 
C3 with
NS or NS-gEnull, respectively); however, gC mutant virus
lacking both domains was even more susceptible to com-
plement (1.58 log
 
10
 
,
 
 P 
 
#
 
 0.001, comparing NS-gC
 
D
 
C5/
P,C3 with NS or gE null virus) and significantly more sus-
ceptible than either single gC mutant virus (NS-gC
 
D
 
C5/
P,C3 versus NS-gC
 
D
 
C5/P or NS-gC
 
DC3, P # 0.003;
Fig. 4). We conclude that both gC domains are important
in complement regulation, as the gC double mutant virus
was more susceptible to complement than either single
mutant virus alone.
gC Domains that Interact with Complement Are Virulence
Factors In Vivo. Studies were performed to determine if
the complement-interacting domains are virulence factors
in vivo using the murine flank model (26, 35). Fig. 5, A
and B show inoculation site and zosteriform disease scores,
respectively, for complement-intact mice infected with 5 3
104 PFU of NS or gC mutant viruses. Disease scores at the
inoculation and zosteriform sites are lower for mutant virus
NS-gCDC5/P than for NS (P # 0.02 for days 4–8 at the
inoculation site, and P , 0.001 for day 5 at the zosteriform
site), supporting the conclusion that the C5/P domain is
a virulence factor. Even greater differences were detected
comparing NS-gCDC3 or double mutant virus NS-gCDC5/
P,C3 with NS (P , 0.001 for days 5–8 at the inoculation
and zosteriform sites). Notably, NS-gCDC3 virus caused
significantly less disease than NS-gCDC5/P virus (P , 0.001
for days 6–8 at the inoculation and zosteriform sites). We
conclude that both gC domains have a significant effect on
disease severity; however, the C3 domain is more impor-
tant because the mutant virus lacking this domain is signifi-
cantly less virulent than the C5/P mutant virus and is as
impaired as the double mutant virus.
Experiments were performed in C3 knockout mice to
determine if interactions between gC and complement ac-
count for the lowered virulence of gC mutant viruses. Vir-
ulence of gC mutant viruses should be similar to wild-type
virus in C3 knockout mice, as C5, P, or C3 cannot be-
come activated. Fig. 5, C and D show that virulence for
each of the mutant viruses is comparable to wild-type virus
in C3 knockout mice.
As further evidence for the importance of the interaction
between gC and complement, C3 knockout mice were re-
constituted with C3. Total hemolytic complement activity
was undetectable in serum from C3 knockout mice; how-
ever, after injection of human C3, total hemolytic comple-
ment activity was restored to levels detected in complement-
intact animals (result not shown). Fig. 5, E and F show that
Figure 6. Photographs of denuded flanks of mice 6 d after infection.
(A) NS in a complement-intact C57BL/6 mouse showing .10 lesions at
the zosteriform site. (B) NS-gCDC5/P,C3 in a complement-intact
C57BL/6 mouse showing no lesions. (C) NS in a C3 knockout mouse
showing .10 zosteriform lesions. (D) NS-gCDC5/P,C3 in a C3 knock-
out mouse showing .10 zosteriform lesions. (E) NS in a C3 knockout
mouse reconstituted with human C3 showing .10 zosteriform lesions.
(F) NS-gCDC5/P,C3 in a C3 knockout mouse reconstituted with human
C3 showing no lesions.1642 Immune Evasion by HSV-1 gC Domains that Interact with Complement
the gC double mutant virus NS-gCDC5/P,C3 is markedly
less virulent in C3 knockout mice reconstituted with C3,
whereas the virulence of wild-type virus is unchanged
(comparing NS and gC double mutant virus: inoculation
site lesions, P , 0.05 on day 3, P , 0.01 on day 4, and P ,
0.001 on days 5–8, whereas for zosteriform lesions, P ,
0.001 on days 5–8).
Fig. 6 shows photographs of flank lesions on day 6 after in-
fection. The left panels show NS, and the right panels show
NS-gCDC5/P,C3, demonstrating that lesions caused by NS
are comparable in the presence or absence of complement,
whereas lesions produced by the gC mutant virus are greatly
affected by complement. These experiments illustrate the im-
portant role of gC–complement interactions in pathogenesis.
Defining the Magnitude of the gC–Complement Effect on
Virulence. Experiments were performed using NS and gC
double mutant virus NS-gCDC5/P,C3 to compare disease
scores over a range of inocula. In Fig. 7, the disease scores
are expressed as the average cumulative disease scores from
days 3–8 after infection (26). In complement-intact mice,
infection with 5 3 105 PFU of the gC double mutant virus
produced a disease score of 19.3 6 1.9 at the inoculation
site (Fig. 7 A). Producing a comparable disease score required
50-fold less wild-type virus. Infection with 5 3 104 PFU of
gC double mutant virus resulted in a disease score of 8.9 6
0.9, which also correlated with the disease caused by 50-
fold less wild-type virus. Similarly, z50-fold less NS than
gC mutant virus was required to produce comparable zos-
teriform disease (Fig. 7 B). In marked contrast, in C3 knock-
out mice, no significant differences were noted comparing
wild-type and gC mutant viruses (Fig. 7, C and D). We
conclude that domains on gC that interact with comple-
Figure 7. Disease scores in complement-intact and C3 knockout mice infected with NS or NS-gCDC5/P,C3 at 5 3 102–5 3 105 PFU. Disease scores
are plotted as the average cumulative scores 6 SEM for days 3–8 after infection at the inoculation site and for days 4–8 at the zosteriform site. A and B
represent disease scores at the inoculation and zosteriform sites, respectively, in complement-intact mice. The numbers of NS (WT) animals evaluated at
each dose were n 5 4 at 5 3 105 PFU, n 5 8 at 5 3 104 PFU, n 5 5 at 5 3 103 PFU, and n 5 4 at 5 3 102 PFU. C5/P,C3 represents gC double mutant
virus NS-gCDC5/P,C3. The numbers of gC double mutant virus-infected mice evaluated were n 5 4 at 5 3 105 PFU, n 5 14 at 5 3 104 PFU, n 5 3
at 5 3 103 PFU, and n 5 4 at 5 3 102 PFU. C and D represent disease scores at the inoculation and zosteriform sites, respectively, in C3 knockout mice.
For wild-type virus, the number of animals evaluated was n 5 4 except at 5 3 105 PFU, where n 5 3. For NS-gCDC5/P,C3 the numbers of animals eval-
uated were n 5 4 at 5 3 105 PFU, n 5 10 at 5 3 104 PFU, n 5 4 at 5 3 103 PFU, and n 5 3 at 5 3 102 PFU.1643 Lubinski et al.
ment account for a 50-fold effect on virulence in comple-
ment-intact animals, whereas in C3 knockout animals, the
domains have no effect. Notably, NS disease scores are vir-
tually identical in complement-intact and C3 knockout
mice (comparing the scores for wild-type virus in Fig. 7, A
with C or B with D), which indicates that gC comple-
ment–interacting domains are remarkably effective in pro-
tecting wild-type virus from complement attack.
Discussion
We have previously defined a role for gC in binding C3
(8, 9, 19), accelerating the decay of the alternative pathway
C3 convertase (20) and interfering with the interaction of
C5 and P with C3b (9, 21). We showed that gCnull virus
is highly susceptible to complement neutralization even in
the absence of antibodies and that gCnull virus is less viru-
lent in mice and guinea pigs (23, 26). We now address the
contribution to pathogenesis of two gC domains that inter-
act with complement by constructing gC mutant viruses
lacking the C5/P blocking domain, the C3 binding do-
main, or both domains.
The murine studies indicate that each of the single mu-
tant viruses is significantly less virulent than wild-type virus;
however, the C3 binding domain mutant virus is clearly the
more important, as this mutant virus was as attenuated as
the gC double mutant virus. Fig. 8 A presents a model of
complement inhibition mediated by gC domains. In vivo,
NS-gCDC5/P mutant virus is only moderately less virulent
than wild-type virus, suggesting that gC affects more than
C5 and P binding to C3b, such as accelerating the decay of
the alternative pathway C3 convertase, C3bBb (20), or per-
haps other C3-mediated functions yet to be determined
(Fig. 8 B). The deletion of the C3 binding domain elimi-
nates gC binding to C3b (Fig. 8 C), rendering the C5/P
domain ineffective because it lacks proximity to C3b and
cannot hinder C5 and P binding. Therefore, a C3 binding
domain mutant virus should be as impaired as a double mu-
tant virus (Fig. 8 D). The model explains our in vivo results,
but it fails to explain why the C3 binding mutant virus was
not as impaired as the double mutant virus in neutralization
assays performed in vitro. A possible explanation is that the
main effect of gC in vivo may be on a function other than
neutralization, such as preventing complement lysis of in-
fected cells (24).
Our results definitively demonstrate that gC is a viru-
lence factor because it regulates complement activation. This
conclusion is based on observations that gC mutant viruses
are significantly less virulent than wild-type virus in com-
plement-intact mice, whereas virulence is comparable to
that of wild-type virus in C3 knockout mice. Proof for the
requirement for C3 was shown by C3 reconstitution ex-
periments in which C3 reduced virulence of the gC double
mutant virus but had no effect on wild-type virus. The
magnitude of the gC effect was addressed by evaluating le-
sion scores using inoculation titers ranging from 5 3 105 to
Figure 8. Models showing how
gC domains that interact with com-
plement block complement activa-
tion. (A) Wild-type gC: the cell
surface activates the complement cas-
cade, resulting in C3b fixation on the
cell surface. gC regions I–IV bind to
C3b, leading to accelerated decay of
C3 convertase (20), or inhibit other
C3-mediated activities, and the NH2
terminus C5/P blocking domain pre-
vents the interaction of C5 and  P
with C3b (9, 21). (B) gCDC5/P: gC
regions I–IV bind to C3b and inhibit
complement activation as in A,
whereas the absence of the C5/P
blocking domain permits C5 and P
binding to C3b, leading to increased
complement activation. The net ef-
fect is partial inhibition of comple-
ment activation. (C) gCDC3: gC
does not bind to C3b; therefore, C3
convertase or other C3-mediated ac-
tivities are not affected. The C5/P
blocking domain is ineffective be-
cause it lacks proximity to C3b and
cannot block C5 and P binding. The
result is that gCDC3 is as susceptible
to complement as gCDC5/P,C3,
shown in D.1644 Immune Evasion by HSV-1 gC Domains that Interact with Complement
5 3 102 PFU. In complement-intact mice, 50-fold more
gC double mutant virus was required to cause disease com-
parable to that caused by wild-type virus.
In vitro studies indicate that gC is also involved in the
initial stage of virus attachment to cells by binding to hepa-
ran sulfate (38, 39). In the absence of gC, gB can mediate
this effect (38), but a role for gC in attachment has not
been established in vivo. Our results indicate that the do-
mains deleted from the gC mutant viruses do not play an
important role in attachment, because in C3 knockout
mice, the mutant viruses are as virulent as wild-type virus.
Of particular interest is the C5/P deletion mutant virus.
This mutant virus lacks gC amino acids 33–123, identified
as an important domain for gC-mediated attachment to
heparan sulfate in vitro (40). Yet this virus shows no differ-
ence in virulence from wild-type virus in C3 knockout
mice, suggesting that this domain is not important for virus
attachment in vivo.
Disease at the inoculation site develops by day 3 after in-
fection, and zosteriform disease generally appears on day 5
(6, 26). We scored inoculation site and zosteriform disease
separately so that we could better evaluate early stages of in-
fection. Interestingly, disease scores at the inoculation site of
the C3 single and double mutant viruses did not differ from
wild-type virus until day 5. This result suggests that the com-
plement effect on gC mutant virus cannot be detected until
rather late after infection. Several explanations are possible. If
complement lyses infected cells rather than inhibiting cell
free virus, it may take several days until enough cells are in-
fected to create an observable effect. Another possible expla-
nation is that complement concentrations may be too low at
the inoculation site early in infection, whereas at later time
points, virus-induced tissue injury leads to an increase in vas-
cular permeability and higher levels of complement proteins.
Additional considerations include that complement may be
mediating its effects by stimulating chemotaxis or other
proinflammatory events that may take several days to de-
velop, or that antibodies may be required to augment the ef-
fects of complement. This last explanation seems unlikely in
view of in vitro results that demonstrate that antibodies are
not required for complement-mediated neutralization or ly-
sis of infected cells (23, 24).
We have previously described a humoral immune evasion
domain on glycoprotein gE that inhibits IgG Fc-mediated
functions (4–6). We showed that gE blocks complement-
enhanced antibody neutralization, reducing the effective-
ness of antibody 100-fold in vitro and offering highly sig-
nificant protection to the virus or virus-infected cell against
antibodies in vivo (6). The results of this study indicate that
complement has little effect on wild-type virus, as disease
scores of wild-type virus are virtually identical in C3 knock-
out and complement-intact mice. Immune evasion medi-
ated by gC and gE may underlie the long held view that
humoral immunity is relatively unimportant in HSV-1
pathogenesis (41). These immune evasion molecules render
the Fc domain of antibody and the complement cascade far
less effective in host defense. These observations have im-
portant implications for vaccines and chemotherapy. They
explain why antibodies and complement are poorly protec-
tive against HSV infection and provide potential targets for
therapies to block HSV-1 immune evasion and render the
virus more susceptible to innate and acquired immunity.
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